The short answer: a marker pattern, not a job description
A flow cytometry result that reads CD3-negative with CD16 and/or CD56 positive identifies a cell population by its surface markers—its immunophenotype. It does not, by itself, show whether those cells are killing targets, making cytokines, or malignant. A concrete example makes the difference clear: one blood sample can contain cells that lack CD3 and carry CD16 and/or CD56, and a flow cytometer can count and characterise cells with that phenotype; asking what those cells do when stimulated is a separate assay.
The CDC’s revised guidelines for CD4+ T-cell determinations—an older methods document, not a current clinical guideline—include the immunophenotypic definition of NK cells as CD3-negative and CD16 and/or CD56-positive. Mayo Clinic Laboratories’ test catalog describes a quantitative blood test for NK/NKT subsets using CD3 negativity and CD16/CD56 markers. Together, those named sources support the core identification rule: the marker combination defines the population.
What the cytometer measures
Flow cytometry measures cells one at a time. Fluorescent antibodies bind chosen surface markers; as cells pass a laser, detectors record the fluorescence signal from each cell. The readout is therefore cell-by-cell, not a single bulk value. Gating is the analysis step where boundaries are drawn around populations on plots of those measurements. For NK-cell flow cytometry, the CDC definition makes the marker logic explicit: look for cells that are CD3-negative and then for CD16 and/or CD56. The “and/or” matters: the definition does not require every cell in the population to carry both CD16 and CD56.
The gate turns measurements into a defined population
A gate is a decision rule: cells inside the boundary are counted as part of the population; cells outside are not. In practical terms, the reported NK-cell result is shaped by the gate and the markers used to set it. The CDC document supports the immunophenotypic definition, but a phenotype definition is not a clinical diagnosis. Mayo’s test page makes one limit explicit for its quantitative NK/NKT subset test: the test is not intended for diagnosis or classification of NK malignant disease.
What a result can and cannot tell you
A quantitative NK/NKT subset result reports information about cells with the defined phenotype in blood, as described by Mayo’s test catalog. That is useful for the question the test is designed to answer: how many cells with that phenotype are present or how the subsets are distributed, within the scope of that test. It does not answer a different question—whether those cells are malignant—because Mayo’s page explicitly says the test is not for NK malignancy diagnosis or classification. It also does not answer a functional question. For that, flow cytometry can be used with a stimulus and a functional readout, but the assay is no longer just counting a surface phenotype.
Functional NK-cell flow cytometry asks a different question
A methods article on functional analysis of human NK cells by flow cytometry describes three practical elements: CD107a degranulation, K562 target-cell stimulation, and cytokine readouts. CD107a is used as a marker of degranulation—the release of granule contents. In such an assay, cells are stimulated, and the cytometer measures a response signal. The authors explicitly caution that degranulation is not the same as target-cell lysis. That is a crucial distinction: a CD107a signal can show that granule release occurred under the assay conditions, but it is not a direct measurement of target-cell killing. The same logic applies to cytokine readouts: they show cytokine production under the assay conditions, not a full cytotoxicity result.
Phenotype and function at a glance
Swipe or scroll to read the full table →
| Question | Flow cytometry readout | What it establishes | What it does not establish by itself |
|---|---|---|---|
| Which cells carry the NK-associated marker pattern? | CD3-negative with CD16 and/or CD56 | A population defined by that immunophenotype; the CDC uses this definition, and Mayo’s test catalog describes quantitative NK/NKT subsets in blood | Malignancy diagnosis or classification; Mayo’s page explicitly excludes that use for its test |
| Are cells degranulating after stimulation? | CD107a after target-cell stimulation | A degranulation response in the assay; the methods article describes this readout | Target-cell lysis; the authors explicitly say degranulation is not the same as lysis |
| Are cells producing cytokines after stimulation? | Cytokine readouts | Cytokine production under the assay conditions; the methods article lists cytokine readouts | A full cytotoxicity result; cytokine production and killing are different readouts |
Why the marker combination is used
The CD3-negative, CD16/CD56-positive combination gives a defined way to identify an NK-cell population for flow cytometry. CD3 negativity excludes cells carrying the CD3 marker, while CD16 and/or CD56 provide the positive markers named in the CDC definition and used in Mayo’s quantitative subset test. That is a phenotype rule, not a functional or diagnostic verdict: a marker-defined count answers a marker-defined question.
What to take away
For a non-specialist reading an NK-cell flow cytometry report, the key is to separate three layers. The marker combination defines the population. The gate turns the measurements into a reported population. The functional assay, if done, uses stimulation and a readout such as CD107a or cytokines to ask what the cells do. No one layer automatically answers the next. That is why a CD3-negative, CD16 and/or CD56-positive result should be read as an immunophenotype result first, with malignancy and function treated as separate questions.
Educational note: This is general information about laboratory methods, not medical advice.